Antiangiogenic therapy in malignant gliomas

Current Opinion in Oncology

Volumn 20, Issue 6, 2008, Pages 652-661

  Norden, Andrew D ^a,b,c,d   Drappatz, Jan ^a,b,c   Wen, Patrick Y ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Glioblastoma; Malignant glioma

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; AFLIBERCEPT; ANTICONVULSIVE AGENT; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CELECOXIB; CILENGITIDE; DASATINIB; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; HYDROXYUREA; IMATINIB; IRINOTECAN; ISOTRETINOIN; LENALIDOMIDE; LOMUSTINE; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; REGENERON; SORAFENIB; SUNITINIB; TANDUTINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB; XL 184; XL184;

ANAPLASTIC CARCINOMA; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; GLIOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM METASTASIS; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55749093799     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32831186ba     Document Type: Review

References (84)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
2. Prados MD, Gutin PH, Phillips TL, et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys 1992; 23:3-8.
3. Prados MD, Seiferheld W, Sandler HM, et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radial Oncol Biol Phys 2004; 58:1147-1152.
4. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24:2715-2722.
5. Yung W, Albright R, Oison J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83:588-593.
6. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999; 17:2762-2771.
7. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17:2572-2578.
8. Ferrara N, Kerbel R. Angiogenesis as a therapeutic target. Nature 2005; 438:967-974.
9. Gasparini G, Longo R, Toi M, Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2005; 2:562-577.
10. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
11. Folkman J. Angiogenesis. Annu Rev Med 2006; 57:1-18.
12. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8:610-622. This is an excellent and comprehensive review that focuses on preclinical findings in brain tumor angiogenesis.
13. Plate K, Breier G, Weich H, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359:845-848.
14. Stefanik DF, Rizkalla LR, Soi A, et al. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res 1991; 51:5760-5765.
15. Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999; 84:10-18.
16. Millauer B, Shawver LK, Plate KH, et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367:576-579.
17. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284:1994-1998.
18. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6:507-516.
19. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-2049. This is an outstanding review of tumor angiogenesis in general. Much of the material is applicable to brain tumors.
20. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of DII4 inhibits tumour growth by promoting nonproductive angiogenesis. Nature 2006; 444:1032-1037.
21. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-760.
22. Rich JN. Cancer stem cells in radiation resistance. Cancer Res 2007; 67:8980-8984.
23. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66:7843-7848.
24. Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007; 7:733-736. This article comprehensively reviews the literature related to glioma stem cells and their interactions with tumor vasculature.
25. Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007; 67:3560-3564.
26. Stark Vance V. Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma. Neuro-oncol 2005; 7:369.
27. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006; 66:1258-1260.
28. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70:779-787.
29. Guiu S, Taillibert S, Chinot O, et al. Bevacizumab/Irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study. Rev Neurol (Paris) 2008; 164:588-594.
30. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13:1253-1259. This is the first report of a phase II trial of bevacizumab and irinotecan for recurrent malignant gliomas.
31. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25:4722-4729. This report updates the results of the initial phase II trial of bevacizumab and irinotecan for recurrent malignant gliomas.
32. Wagner SA, Desjardins A, Reardon DA, et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. J Clin Oncol 2008; 26:2021.
33. Cloughesy T, Prados M, Wen P, et al. A phase II, randomized, noncomparative clinical trial of bevacizumab alone or in combination with cpt-11 prolongs 6-month pts in recurrent, treatment-refractory glioblastoma. In: Society for Neuro-Oncology 12th Annual Meeting, 2007.
34. Cloughesy TF, Prados MD, Mikkelsen T, et al. A phase II, randomized, noncomparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 2008; 26:2010b. This is the preliminary report of a large, randomized phase II trial in which re-current malignant glioma patients were treated with bevacizumab with or without irinotecan.
35. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008; 26:271-278. In this retrospective cohort study, VEGF expression was shown to correlate with radiographic response but not survival.
36. Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007; 25:4033-4042. This review article addresses the rationale for combining antiangiogenic therapies with cytotoxic chemotherapy and radiation therapy.
37. Lai A, Filka E, McGibbon B, et al. Phase 11 pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008; 71:1372-1380. This is the first reported pilot study of combination therapy with bevacizumab, radiation therapy, and temozolomide.
38. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antrtumor effects. Proc Natl Acad Sci U S A 2002; 99:11393-11398.
39. Wachsberger PR, Burd R, Cardi C, et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 2007; 67:1526-1537.
40. De Groot JF, Wen PY, Lamborn K, et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. J Clin Oncol 2008; 26:2020.
41. Batchelor T, Sorensen AG, Ancukiewicz M, et al. A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2007; 25:2001.
42. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95. In this phase II study of cediranib for recurrent glioblastoma, advanced MRI techniques are used to demonstrate reversible vascular normalization. This represents the first clinical evidence that supports the vascular normalization hypothesis. The authors also report on potential mechanisms of resistance to antiangiogenic therapy, including bFGF, SDF-1 a, and circulating endothelial cells.
43. di Tomaso E, Frosch MP, Auluck PK, et al. Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment. J Clin Oncol 2008; 26:2009.
44. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008; 14:1540-1549. In this study, the authors demonstrate that sunitinib therapy may normalize vasculature and improve penetration of cytotoxic chemotherapy into the tumor. 45 Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23:8136-8139.
45. Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 2007; 7:1537-1560. This review article addresses the possibility that antiangiogenic therapy may promote an invasive phenotype in glioma cells. Preclinical studies and clinical trials are discussed.
46. Yung WKA, Friedman H, Jackson E, et al. A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Proc Am Soc Cin Oncol 2002; 21:315.
47. Kirkpatrick JP, Rich JN, Vredenburgh JJ, et al. Final report: phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG). J Clin Oncol 2008; 26:2057.
48. Nabors LB, Rosenfeld M, Chamberlain M, et al. A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401). J Clin Oncol 2007; 25:2058.
49. Peereboom D, Olson J, Nabors B, et al. NABTT 0502: phase 2 trial of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro-oncol 2007; 9:525.
50. Schiff D, Sarkaria J, Decker P, et al. Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572. Neuro-oncol 2007; 9:518.
51. Desjardins A, Quinn JA, Vredenburgh JJ, et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 2007; 83:53-60.
52. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006; 12:4899-4907.
53. Reardon DA, Cloughsey TF, Raizer JJ, et al. Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol 2008; 26:2051.
54. D'Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91:4082-4085.
55. Fine H, Figg W, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18:708-715.
56. Fine H, Wen P, Maher E, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003; 21:2299-2304.
57. Groves MD, Puduvalli VK, Chang SM, et al. A North American brain tumor consortium (NABTC 99-04) phase H trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme, J Neurooncol 2007; 81:271-277.
58. Fine HA, Kim L, Albert PS, et al. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors, Clin Cancer Res 2007; 13:7101-7106.
59. Browder T, Butterfield C, Kraling B, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-1886.
60. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005; 27:573-581.
61. Kesari S, Schiff D, Doherty L, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-oncol 2007; 9: 354-363. This phase II study found that metronomic therapy with etoposide, cyctophosphamide, thalidomide, and cetecoxib is minimally active in recurrent malignant glioma.
62. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C beta-selective inhibitor, Enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65:7462-7469.
63. Fine HA, Kim L, Royce C, et al. Results from phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 2005; 23:1504.
64. Fine HA, Puduvalli VK, Chamberlain MC, et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): a phase III study. J Clin Oncol 2008; 26:2005.
65. Reardon D, Quinn J, Vredenburgh J, et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005; 103:329-338.
66. Levin V, Giglio P, Puduvalli V, et al. Combination chemotherapy with 13-cisretinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol 2006; 78:85-90.
67. Pannullo SC, Burton J, Serventi J, et al. Phase I/II trial of twice-daily temozolomide and celecoxib for treatment of relapsed malignant glioma: final data. J Clin Oncol 2006; 24:1519.
68. Taga T, Suzuki A, Gonzalez-Gomez I, et al. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002; 98:690-697.
69. Nabors L, Rosenfeld S, Mikkelsen T, et al. A phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas [abstract TA39]. In: Society for Neuro-Oncology Ninth Annual Meeting. Toronto, Canada: Neuro-Oncology; 2004.
70. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of citengitide in patients with recurrent malignant glioma. J Clin Oncol 2007; 25:1651-1657.
71. Gilbert M, Lambom K, Lassman A, et al. Tumor tissue delivery of citengitide after intravenous administration to patients with recurrent glioblastoma (GBM): preliminary data from NABTC protocol 03-02. Neuro-oncol 2007; 9:525.
72. Reardon D, Fink K, Nabors L, et al. An update of the phase lia trial of cilengrtide (EMD121974) single-agent therapy in patients with recurrent glioblastoma: EMD 121974-009. Neuro-oncol 2007; 9:517.
73. Stupp R, Goldbrunner R, Neyns B, et al. Mature results of a phase I/IIa trial of the integrin inhibitor cilengrtide (EMD121974) added to standard concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma. Neuro-oncol 2007; 9:517.
74. Shen Q, Goderie SK, Jin L, et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 2004; 304:1338-1340.
75. Dietrich J, Han R, Yang Y, et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006; 5:22.
76. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61:6624-6628.
77. Lamszus K, Kunkel P, Westphal M. Invasion as limitation to antiangiogenic glioma therapy. Acta Neurochir Suppl 2003; 88:169-177.
78. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2:306-314.
79. Du R, Lu KV, Petritsch C, et al. HIF1 alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13:206-220. This study demonstrates that HIF-Iα is involved in the recruitment of vascular precursor cells to promote GBM angiogenesis. This suggests a potential mechanism of resistance to antiangiogenic therapy.
80. Carlson MR, Pope WB, Horvath S, et al. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 2007; 13:2592-2598. These data suggest that VEGF-independent pathways, perhaps involving neuronal pentraxin-2 and aquaporin-3, may be important predictors of peritumoral edema and survival in a subset of GBM patients.
81. Lassman AB, Iwamoto FM, Gutin PH, Abrey LE. Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM). J Clin Oncol 2008; 26:2028.
82. Zuniga RM, Torcuator R, Doyle T, et al. Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan. J Clin Oncol 2008; 26:13013.
83. Narayana A, Raza S, Golfinos JG, et al. Bevacizumab therapy in recurrent high grade glioma: impact on local control and survival [abstract 13000]. In: American Society of Clinical Oncology Annual Meeting. Chicago, Illinois, USA: J Clin Oncol; 2008.
84. Quant E, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen. J Clin Oncol 2008; 26:2008.